Nir Drayman News Today

A previously tested active ingredient for various illnesses may now become a valuable weapon in the COVID-19 drug quiver. Decreases viral load and is

Existing drug may be effective in treating SARS-CoV-2 Scientists from the University of Chicago have found that the drug masitinib may be effective in treating COVID-19. The drug, which has undergone several clinical trials for human conditions but has not yet received approval to treat humans, inhibited the replication of SARS-CoV-2, the virus that causes COVID-19, in human cell cultures and in a mouse model, leading to much lower viral loads. X-ray crystallography gave us a strong indication ...

Existing drug may be effective in treating COVID-19 A new University of Chicago study has found that the drug masitinib may be effective in treating COVID-19. The drug, which has undergone several clinical trials for human conditions but has not yet received approval to treat humans, inhibited the replication of SARS-CoV-2 in human cell cultures and in a mouse model, leading to much lower viral loads. Researchers at UChicagos Pritzker School of Molecular Engineering (PME), working with collabor...

AB Science SA (Euronext - FR0010557264 - AB) today announces publication of a peer-reviewed article titled ‘ Masitinib is a broad coronavirus 3CL inhibitor that effectively blocks replication of SARS-CoV-2 in the journal Science [1]. The article reports on research that identifies masitinib as a broad antiviral agent capable of treating SARS-CoV-2 (the virus that causes COVID-19), including demonstration of in vivo activity in mice, with efficacy maintained, in vitro, against SARS-CoV-2 va...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. AB Science announces the signing of an exclusive licensing agreement with the University of ... AB ScienceApril 6, 2021 GMT                                                                                                                                                                                           �...